Submissions from 2023
EP03.03-02 Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer, S. K. Alhushki, A. Al-Muhtaseb, H. Abushukair, and Fawzi Abu Rous
Molecular characterization and clinical outcomes of pancreatic neuroendocrine tumors (pNENs) harboring PAK4-NAMPT alterations, Ibrahim Azar, Nishant Gandhi, Misako Nagasaka, Jun Gong, Bassel Nazha, Khalil Choucair, Moh'd M. Khushman, Heloisa P. Soares, Wafik S. El-Deiry, Philip A. Philip, Emil Lou, Alex P. Farrell, Jeffrey Swensen, Matthew J. Oberley, Jim Abraham, Chadi Nabhan, Sanjay Goel, Wolfgang M. Korn, and Anthony F. Shields
P-76 Genomic and transcriptomic characterization of pancreatic neuroendocrine tumors reveals novel therapeutic candidates, A. Azmi, Z. Mahdi, S. Bannoura, M. Al-Hallak, M. Uddin, H. Khan, I. Muqbil, R. Mohammad, H. Chen, Philip A. Philip, and B. El-Rayes
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations, J. Thaddeus Beck, Meredith McKean, Shirish M. Gadgeel, Daniel W. Bowles, Rizwan Haq, Rona Yaeger, Matthew H. Taylor, Arnab K. Maity, Stefanie Drescher, Colleen Oliver, and Ann M. Huelskamp
Single-cell epigenomic analysis reveals an important role of the receptor kinase Ror2 in the erosion of cellular identity during pancreatic carcinogenesis, Simone Benitz, Malak Nasser, Alexander Steep, Ian Loveless, Hui-Ju Wen, Daniel Long, Erick T. Davis, Donald Rempinski, Michaela Louw, Jacee Moore, and Nina Steele
Efficacy of the Addition of RGI-2001 to Tacrolimus and Methotrexate for Acute Gvhd Prevention in Myeloablative HSCT Using HLA-Matched Donors, Yi-Bin Chen, Shatha Farhan, Lazaros J. Lekakis, Gary J. Schiller, Jean Adel Yared, Amer Assal, Dana D. Lee, Hayley Lane, Ted A. Gooley, Zachariah DeFilipp, and Ayman Saad
Incidence of Positive Sentinel Lymph Node in cN0(f) Breast Cancer Patients After Neoadjuvant Chemotherapy: Opportunity to Defer Intraoperative Frozen Section Analysis, Fallon Dimaano, Theresa Schwartz, Laura L. Susick, Elizabeth King MD, Christine Joliat, Anna Lehrberg, Lindsay Petersen, and Jessica Bensenhaver
EP10.01-03 A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC, A. Drilon, M. M. Awad, D. R. Camidge, P. M. Forde, M. Alexander, Shirish M. Gadgeel, L. C. Villaruz, J. Perez, T. Navas, C. Daly, and S. Patel
Expression of Irf3 and Irf7 in tumour cells drives pancreatic cancer development and progression, Lisa Fahr, Simone Benitz, Tobias Straub, Jurik Mutter, Hannah Lisiecki, Ujjwal M. Mahajan, Georg Beyer, Katja Steiger, Andrea Terrasi, Gunnar Schotta, and Axel Imhof
A Single Institution Randomized Clinical Trial Evaluating Ciprofloxacin Versus Levofloxacin As Antibacterial Prophylaxis for Patients Receiving Hematopoietic Stem Cell Transplantation, Shatha Farhan, Peter Xie, Klodiana Neme, Angela German, Nancy Mikulandric, Josena K. Stephen, Mary A. Trapp, Elizabeth A. Henne, Sarah Szymanski, Scott R. Rohrer, Danielle L. Pelland, Nada Zagar, Izabela Z. Mazur, Nada Rida, Kunj Patel, Min Wu, Neda Kortam, Aseel Yaseen, Aroob Sweidan, Josephine Emole, Edward Peres, Muneer H. Abidi, and Mayur Ramesh
MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC, Shirish M. Gadgeel, P. A. Jänne, A. I. Spira, S.-H. I. Ou, R. S. Heist, J. M. Pacheco, M. L. Johnson, J. K. Sabari, K. Leventakos, J. A. Mason, and K. Velastegui
1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A, Shirish M. Gadgeel, T. S. K Mok, S. Peters, E. Nadal, J-Y Han, J. A. Alatorre Alexander, N. Leighl, V. Sriuranpong, M. Pérol, G. D. Castro, and F. de Marinis
OA14.05 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%, Shirish M. Gadgeel, D. Rodríguez-Abreu, B. Halmos, M. C. Garassino, T. Kurata, Y. Cheng, E. Jensen, M. Shamoun, K. Rajagopalan, and L. Paz-Ares
EP12.01-64 Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review, Shirish M. Gadgeel, E. Wang, S. Phani, C. Wu, M. Salas, J. Meng, F. Diamand, S. Esker, and D. W-T Lim
1388P Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC), Shirish M. Gadgeel, Q. Zhang, H. Lin, O. Fajardo, H. Trinh, S. Arndorfer, S. Kong, A. Rahman, S. Li, V. R. Archer, and J. F. Gainor
Characteristics and outcomes of patients with small cell lung cancer (SCLC) detected with CT screening at a single health system, Manasi M. Godbole, Pin Li, Kashmira Wani, Matthew Meranda, Michael J. Simoff, and Shirish M. Gadgeel
Lowering the bar for consideration of neoadjuvant chemotherapy in early-stage HER2- positive breast cancers, Manasi M. Godbole, Matthew Meranda, Kathren Shango, and Vrushali S. Dabak
P2.09-39 Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers, Radhika Gutta, Fawzi Abu Rous, E. Teslow, E. Jaeger, Shirish M. Gadgeel, and Bindu Potugari
43001 Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis, Omid Hamid, Amy Weise, Karl D. Lewis, Tae M. Kim, Meredith McKean, Nehal J. Lakhani, John Kaczmar, Kyriakos P. Papapoulos, Shuquan Chen, Jayakumar Mani, and Giuseppe Gullo
XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers, Erika Hamilton, Alexander Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo Han, Amy Weise, Aubri Marchesani, Kate Josephs, and Arvind Chaudhry
XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers (1250), Erika Hamilton, Alexander Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo Han, Amy Weise, Aubri Marchesani, Kate Josephs, and Arvind Chaudhry
8MO Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency, P. A. Jänne, A. Spira, G. J. Riely, Shirish M. Gadgeel, R. Heist, S. H. I. Ou, M. L. Johnson, J. Sabari, K. Velastegui, J. G. Christensen, W. Yang, K. Anderes, R. Chao, and C. Paweletz
81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study, M. L. Johnson, S. H. I. Ou, E. Felip, C. Baik, B. Besse, J. Mazieres, D. R. Camidge, Shirish M. Gadgeel, A. Drilon, Y. Y. Elamin, G. Liu, J. E. Reuss, T. Kehrig, H. E. Pelish, V. Zhu, and J. J. Lin
A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma, Mandana Kamgar, Husain Y. Khan, Amro Aboukameel, Sahar Bannoura, Brian Y. Chung, Aniko Szabo, Yiwei Li, Mohammed N. Al Hallak, Philip A. Philip, Ben George, Kathleen K. Christians, Douglas B. Evans, Susan Tsai, Beth Erickson, Sanjeev Luther, Asfar S. Azmi, and William A. Hall
A perilous and complicated situation in hospitals: Vitamin D deficiency in multiple myeloma patients-A nationwide cross-sectional study, Manisha R. Lakhanpal, Nikhila Chelikam, Divesh Manjani, Simmy Lahori, Sai A. Akella, Prashanth G. Shivashankar, Shlok V. Shah, Abdirazak Ali, Varneet Toor, Aryak Singh, and Rahul Gujarathi
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers), Michael S. Lee, Aparna R. Parikh, David R. Spigel, Farshid Dayyani, Alexander I. Spira, Chloe E. Atreya, Susanna V. Ulahannan, John H. Strickler, Marwan Fakih, Patrick Grierson, and Eric Christenson
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US), Christopher H. Lieu, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim H. Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Arvind Dasari
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis, Inderjit Mehmi, Karl D. Lewis, Amy M. Weise, Meredith McKean, Kyriakos P. Papadopoulos, John Crown, Sajeve S. Thomas, Eugenia Girda, John M. Kaczmar, Kevin B. Kim, and Nehal J. Lakhani
EFFICACY AND SAFETY OF EPTACOG BETA (RECOMBINANT HUMAN FVIIA) ACCORDING TO AGE IN PERSONS WITH HAEMOPHILIA A/B WITH INHIBITORS UNDERGOING SURGICAL PROCEDURES, W. Miesbach, M. Escobar, L. Boggio, S. Bonanad, G. Castaman, Y. Darguard, A. Giermasz, C. Hermans, Philip Kuriakose, D. Quon, M. Reding, D. Q. Tran, J. Windyga, D. Bonzo, C. Macie, and J. Mahlangu
LUMINOS-102: Lerapolturev with and without α-PD- 1 in unresectable α-PD- 1 refractory melanoma, Justin Moser, Ding Wang, C. L. Cowey, Evan Pisick, Douglas B. Johnson, Joanna Kolodney, Meghan J. Mooradian, Andrew L. Pecora, Andrew S. Poklepovic, Alan Tan, Sajeve S. Thomas, Daniel Corum, Shannon R. Morris, Hannah Kittinger, Jessica Sorrentino, William G. Nichols, and Yana G. Najjar
Closing the Gap on Racial Disparities in Pancreas Cancer -the Impact of a Multidisciplinary Clinic for Surgical Patients with Pancreatic Adenocarcinoma (PDAC) in an Integrated, Tertiary Healthcare System, Georges Nassif, Meng-Hua Tao, Kendyll J. Gartrelle, Julie Clark, Kyra Langley, Farzan Siddiqui, Parag J. Parikh, Gazala Khan, Philip A. Philip, Rupen Shah, Christopher Steffes, and David Kwon
Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922, Michael J. Overman, Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby, Marwan Fakih, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies, Krish Patel, Sarah Rothman, Poulomee A. Das, Stephanie Yee, Indu Ramachandran, Iphigenia Koumenis, Terry A. Cook, Ying Yuan, Nikolaus S. Trede, and Ahmad H. Mattour
Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study, M. R. Patel, T. Doi, T. Koyama, G. S. Falchook, C. F. Friedman, S. A. Piha-Paul, M. Gutierrez, M. M. Awad, Abdelwahab H. Mattour, T. Satoh, and N. Okamoto
P2.06-08 Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab, A. Qin, D. Morgensztern, S. Waqar, D. Owen, Shirish M. Gadgeel, B. Schneider, G. Kalemkerian, J. Rice, and N. Ramnath
A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613, Kanwal P. S Raghav, Katherine A. Guthrie, Scott Kopetz, Benjamin R. Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman, Arvind Dasari, Larry R. Corum, Lee G. Hicks, Mital Patel, Benjamin T. Esparaz, Syed Mohammad A. Kazmi, Nitya Alluri, Sarah Colby, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation-ECOG-ACRIN EA2192, Kim A. Reiss, Sung C. Hong, Anup Kasi, Eileen M. O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J. Klempner, Susan M. Domchek, Paul J. Catalano, E. Gabriel Chiorean, Philip A. Philip, and Peter J. O'Dwyer
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non-small cell lung cancer (NSCLC), Joshua E. Reuss, Sunil G. Gandhi, David R. Spigel, Pasi A. Janne, Luis G. Paz-Ares, Shirish M. Gadgeel, Jyoti D. Patel, Francesco Passiglia, Alexander I. Spira, Martin J. Edelman, and George R. Blumenschein
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study, Dan-yun Ruan, Myung A. Lee, Yanhong Deng, Keun-Wook Lee, Michael Millward, Jaspreet S. Grewal, Shirish M. Gadgeel, Rachel E. Sanborn, Xinfang Hou, Shaozhong Wei, and Seok J. Huh
Expression of lysine demethylase 5a (Kdm5a) influences tumour aggressiveness in murine pancreatic cancer cells, Nicole Schreiner, Lisa Fahr, Simone Benitz, Quan Zhou, Ahmed Alnatsha, Axel Imhof, Ujjwal Mahajan, Julia Mayerle, and Ivonne Regel
SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers, Rachna T. Shroff, Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind M. Javle, Carol Aghajanian, Benjamin R. Tan, Puneet S. Cheema, Anuj K. Patel, Renuka V. Iyer, Robin K. Kelley, Jaykumar R. Thumar, Anthony B. El-Khoueiry, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
OA10.03 Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective, E. K. Singh, A. Desai, Fawzi Abu Rous, and J. Feldman
False positive PET scan in patients with treated malignancy following COVID-19 vaccination, Alexander A. Slota, Vrajesh Parmar, Amy M. Weise, and Ding Wang
2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC), S Sridhar, P. H. O'Donnell, T. W. Flaig, J. E. Rosenberg, C. J. Hoimes, M. I. Milowsky, S. Srinivas, S. George, R. R. McKay, D. P. Petrylak, and P. M. Coelho Barata
Polygenic risk scores in assessing lung cancer susceptibility in non-Hispanic White and Black populations, Matthew R. Trendowski, Chrissy Lusk, Angie Wenzlaff, Christine Neslund-Dudas, Shirish M. Gadgeel, Ayman Soubani, and Ann G. Schwartz
Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/ NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogenactivated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers), Susanna V. Ulahannan, David R. Spigel, Michael S. Lee, Marwan Fakih, Patrick Grierson, Eric Christenson, E. Gabriela Chiorean, Darryl A. Outlaw, Gazala Khan, Chloe E. Atreya, and Aparna R. Parikh
A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC), Leah Wells, Angel Qin, John Rice, Shirish M. Gadgeel, Bryan J. Schneider, Nithya Ramnath, Lili Zhao, and Gregory P. Kalemkerian
Modeling Risk of Atrial Fibrillation in Stem Cell Transplant, Min Wu, Rayli Pichardo, Sowjanya Vuyyala, Josephine Emole, Edward Peres, Muneer H. Abidi, Madhulata Reddy, and Shatha Farhan
Submissions from 2022
Racial and gender disparities in next-generation sequencing for pancreatic adenocarcinoma, Fawzi Abu Rous, Sunny R. K Singh, Chun-Hui Lin, Laila M. Poisson, and Gazala Khan
(P44) Is Prophylactic Cranial Irradiation Necessary in Stage I-IIA Small Cell Lung Cancer Patients? A Single Institution Experience, Sondos Alkhatib, Aharon Feldman, Shirish M. Gadgeel, Andrew Popoff, Munther Ajlouni, Michael Simoff, and Benjamin Movsas
1544P Pre-treatment CT radiomics predicts survival in chemo-immunotherapy-treated small cell lung cancer, Joseph Bae, Prateek Prasanna, and Shirish M. Gadgeel
An Unsupervised Autoencoder Developed from Dynamic Contrast-Enhanced (DCE)-MRI Datasets for Classification of Acute Tumor Response in an Animal Model, Hassan Bagher-Ebadian, Tavarekere N. Nagaraja, Glauber Cabral, Katelynn G. Farmer, Olivia Valadie, P. Acharya, Benjamin Movsas, Stephen L. Brown, Indrin J. Chetty, and James R. Ewing
Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer, Z. Bakouny, P. Grover, C. Labaki, J. Awosika, S. Gulati, C. Y. Hsu, M. A. Bilen, O. Eton, L. Fecher, Clara Hwang, H. Khan, R. R. McKay, E. Ruiz, L. Weissmann, M. A. Thompson, D. Shah, J. Warner, Y. Shyr, T. K. Choueiri, and T. Wise-Draper
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS mutation, Tanios S. Bekaii-Saab, Alexander I. Spira, Rona Yaeger, Gary L. Buchschacher, Autumn Jackson McRee, Joshua K. Sabari, Melissa L. Johnson, Minal A. Barve, Navid Hafez, Karen Velastegui, James G. Christensen, Thian Kheoh, Hirak Der-Torossian, and Igor I. Rybkin
Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study, B. Besse, M. Johnson, S. H. I. Ou, Shirish M. Gadgeel, A. Spira, J. Lin, E. Felip, A. J. van der Wekken, A. Calles, M. J. de Miguel, D. R. Camidge, Y. Elamin, G. D. L. Lopes, S. Liu, J. Bauman, D. Haggstrom, G. Riley, H. E. Pelish, V. W. Zhu, and A. Drilon
Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors, A. Drilon, B. Besse, D. R. Camidge, S. H. I Ou, Shirish M. Gadgeel, M. L. Johnson, A. Calles, M. J. de Miguel, A. I. Spira, E. Felip, G. Lopes, A. J. van der Wekken, Y. Y. Elamin, J. Green, Y. Sun, J. Soglia, V. W. Zhu, and J. J. Lin
EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study, A. Drilon, S. H.I Ou, Shirish M. Gadgeel, M. Johnson, A. Spira, G. Lopes, B. Besse, E. Felip, A. J. van der Wekken, A. Calles, M. J. de Miguel, D. R. Camidge, Y. Elamin, S. Liu, J. Bauman, D. Haggstrom, G. Riley, H. E. Pelish, V. W. Zhu, and J. J. Lin
Does contralateral prophylactic mastectomy improve survival in triple negative breast cancer?, Genevieve A. Fasano, Solange Bayard, Yalei Chen, Jennifer Marti, Rache Simmons, Alexander Swistel, Jessica Bensenhaver, S. David Nathanson, Lindsay Petersen, Erica Proctor, and Melissa Davis
1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC), Shirish M. Gadgeel, J. Al-Mondhiry, M. J. Ahn, S. W. Kim, L. Paz-Ares, H. Prenen, M. Boyer, J. G. Bustamanta Alvarez, B. Solomon, S. Huang, M. Minocha, M. Kistler, and N. Hashemi Sadraei
Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD), Shirish M. Gadgeel, J. Gainor, F. Cappuzzo, E. Garralda, D. H. Lee, J. Mazieres, D. W. Kim, V. Zhu, G. Lopes, S. Miller, M. Nowicka, H. Trinh, S. M. Arndorfer, A. Rahman, J. Noe, Q. Zhang, and V. Subbiah
973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC, M. C. Garassino, Shirish M. Gadgeel, G. Speranza, E. Felip, E. Esteban Gonzalez, M. Domine Gomez, M. J. Hochmair, S. F. Powell, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. B. Garon, T. Kurata, J. E. Gray, P. O. Schwarzenberger, E. Jensen, and D. Rodriguez Abreu
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes, Laura Graham, Edward Green, Joseph J. Park, Olesia Kellezi, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Deepak Kilari, Melissa Clingerman, Abhishek Tripathi, and Matthew Labriola
The role of African Duffy-null allele related inflammation on the tumor microenvironment, Yanira Guerra, Rachel Martini, Jessica Bensenhaver, Yalei Chen, Joseph K. Oppong, Ishmael Kyei, Frances S. Aitpillah, Michael O. Adinku, Joseph K. Oppong, Ernest K. Adjei, and Aisha Jibril
A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19, S. Halabi, B. Luo, H. Dzimitrowicz, Clara Hwang, T. M. Wise-Draper, C. Labaki, R. R. McKay, E. Ruiz, C. Rangel-Escareño, D. Farmakiotis, E. A. Griffiths, C. T. Jani, M. Accordino, C. Friese, E. Wulff-Burchfield, M. Puc, P. Yu, U. Topaloglu, S. Mishra, and J. Warner
790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel), O. Hamid, Amy Weise, T. M. Kim, M. A. Mckean, N. J. Lakhani, J. Kaczmar, K. P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab in advanced melanoma, O. Hamid, Amy Weise, T. M. Kim, M. McKean, N. J. Lakhani, J. Kaczmar, K. P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study, Vadim S. Koshkin, Guru P. Sonpavde, false Hwang, Begona Mellado, Gareth Tomlinson, Masashi Shimura, Michael J. Chisamore, Maciej Gil, and Yohann Loriot
OA06.06 Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis, A. Kulkarni, C. Hennessy, G. Wislon, V. Ramesh, Clara Hwang, A. Joy, Z. Bakouny, H. Khan, D. Vilar-Compte, R. McKay, C. Jani, J. W. Riess, M. Puc, A. Kasi, S. Berg, D. R. Castillo, B. Hayes-Lattin, W. Hosmer, D. Flora, S. Mishra, B. French, J. Warner, G. Lopes, S. Peters, and N. Duma
43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy, T. A. Leal, D. Berz, Igor I. Rybkin, W. T. Iams, D. Bruno, C. Blakely, A. Spira, M. Patel, D. M. Waterhouse, D. Richards, A. Pham, R. Jotte, E. B. Garon, D. S. Hong, R. Shazer, X. Yan, L. Latven, and K. He
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT), N. Ohri, S. Jolly, B. T. Cooper, R. Kabarriti, W. R. Bodner III, J. Klein, S. Viswanathan, R. Kaufman, E. Shum, J. K. Sabari, H. Cheng, R. Gucalp, E. Castellucci, A. Qin, Shirish M. Gadgeel, and B. Halmos
Sentinel Lymph Node Positivity in Clinically Node Negative Breast Cancer Patients After Neoadjuvant Chemotherapy: Opportunities to Defer Intraoperative Frozen Section Analysis, Omar Qutob, Jessica Bensenhaver, Laura L. Susick, Lindsay Petersen, Anna Lehrberg, Fallon Dimaano, and Theresa Schwartz
Disparity Outcomes in Patients Undergoing Pancreas Surgery at an Urban Tertiary Care Center, Mariam A. Saad, Kendyll J. Gartrelle, Rupen Shah, Julie Clark, Kyra Langley, Erin Field, Christopher P. Steffes, and David S. Kwon
A single-center analysis of 30- and 90-day post-pancreatectomy complications in patients undergoing neoadjuvant radiation with EBRT versus MRI-guided SBRT, Mariam Saad, Julie Clark, Rupen A. Shah, Farzan Siddiqui, Parag J. Parikh, Kendyll J. Gartrelle, Abdul Kader Natour, Gazala Khan, and David Kwon
Evaluation of Practice Patterns and Outcomes after Implementing SMART for Pancreatic Cancer, Eric Schaff, Parag J. Parikh, Pin Li, Rupen Shah, Gazala Khan, Farzan Siddiqui, Benjamin Movsas, and David Kwon
Update on a pilot study: Flumeltbi peripheral blood HLAhaploidentical stem cell transplantation with post-transplant cyclophosphamide and bortezomib (Cy2Bor3), Sowjanya Vuyyala, Edward Peres, Klodiana Neme, Nancy Mikulandric, Susan M. Wautelet, Danielle L. Pelland, Nada Zagar, Mary A. Trapp, Scott R. Rohrer, Elizabeth A. Henne, Sarah Szymanski, Josephine Emole, Muneer H. Abidi, and Shatha Farhan
Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts), Zeynep B. Zengin, Nicholas Henderson, Joseph J. Park, Alicia Ali, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Laura Graham, Deepak Kilari, Abhishek Tripathi, and Matthew Labriola
Submissions from 2021
Satisfaction of hem/onc patients with video visits during the COVID-19 pandemic at a tertiary care center in Michigan, Fawzi Abu Rous, Pin Li, Mohamed Elgamal, Hussna Abunafessa, Rebecca Chacko, Sowjanya Vuyyala, Yaser Alkhatib, and Philip Kuriakose
O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup, J Ajani, F El Hajbi, D Cunningham, M Alsina, P Thuss-Patience, G Scagliotti, M Van den Eynde, Igor Rybkin, L Shen, K Kato, S Kim, S D'Alonzo, W Yu, A Tao, and E Van Cutsem
1317P Renal toxicity in black patients with non-squamous non-small cell lung cancer treated with combination platinum-pemetrexed-pembrolizumab therapy, Nino Balanchivadze, Zeinab Nasser, Muhammad Shahid, Cortney McKay, Pin Li, Ryann Sohaney, and Shirish M. Gadgeel
P08.04 Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors, L Bazhenova, N Girard, A Minchom, S Ou, Shirish M. Gadgeel, J M. Trigo, S Viteri, A Londhe, P Mahadevia, and J Bauml
A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIb/Iv nonsmall cell lung cancer (NSCLC): The landscape 1011 trial in progress, Michael Boyer, Sandip Patel, Thomas Marron, Nick Pavlakis, Sagun Parakh, Shirish Gadgeel, Michael Shafique, Robert Hoyer, D. Ross Camidge, Charles Farber, and Ranee Mehra
Molecular Biomarker Testing and Targeted Therapy Patterns in Patients with Acute Myelogenous Leukemia (AML) in Community Health Systems in the United States: A Real-World Data Analysis, Francesca Coutinho, Zartash Gul, Anna B. Berry, Michael A. Thompson, Christopher A. Willner, Sowjanya Vuyyala, Haley McCracken, Katherine Geverd, Jeanna Wallenta Law, Frank M. Wolf, Thomas D. Brown, and Philip Kuriakose
1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C, R Dziadziuszko, S Peters, Shirish M. Gadgeel, S M. Shagan, E Felip, A Morabito, P Cheema, M C. Dols, Z Andric, C H. Barrios, M Yamaguchi, E Dansin, P Danchaivijitr, M Johnson, S Novello, D R. Gandara, E Schleifman, J Wang, and T S.K. Mok
1632P At home androgen deprivation therapy for patients with prostate cancer during the COVID-19 pandemic. One center experience, T Esakia, T Melkadze, K Tsiklauri, E Mariamidze, S Tsitsilashvili, N Otkhozoria, M Abuladze, N Jokhadze, and Nino Balanchivadze
Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189, Shirish Gadgeel, Jhanelle Grey, Maria Teresa Rizzo, Patrick Peterson, Jongseok Kim, and Delvys Rodríguez-Abreu
P10.03 Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis of Key Prognostic Factors, Shirish M. Gadgeel, M Izano, C Sweetnam, Igor Rybkin, M Hendawi, J Weese, A Patel, D Reding, J Treisman, A Stafford, F Wolf, C Zhang, and T Brown
MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC), J F. Gainor, G Curigliano, D W. Kim, D H. Lee, B Besse, C S. Baik, R C. Doebele, P Cassier, G Lopes, D SW Tan, E Garralda, L Paz-Ares, B C. Cho, Shirish M. Gadgeel, M Thomas, S V. Liu, C Clifford, H Zhang, C D. Turner, and V Subbiah
KRAS mutations in patients with nonsquamous non-small-cell lung cancer: Prevalence and relationship with PD-l1 expression, tumor mutation burden and smoking status, Marina C. Garassino, Delvys Rodriguez-Abreu, Shirish M. Gadgeel, Dariusz M. Kowalski, Kazuo Kasahara, Enriqueta Felip, Yi-Long Wu, Gilberto de Castro, Byoung Chul Cho, Hande Z. Turna, and Hidehito Horinouchi
MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations, N Girard, L Bazhenova, A Minchom, S Ou, Shirish M. Gadgeel, J Trigo, S Viteri, G Li, P Mahadevia, A Londhe, D Backenroth, T Li, and J M. Bauml
61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199, J N. Graff, S Tagawa, C Hoimes, W Gerritsen, U N. Vaishampayan, T Elliott, Clara Hwang, A J.T. Tije, A G. Omlin, R S. McDermott, R De Wit, P Qiu, C Poehlein, J Kim, L Suttner, R Cristescu, M J. Marton, C Schloss, J S. de Bono, and E S. Antonarakis
Phase 1 trial of SQ3370 in solid tumors, Alexander Guminski, Ding Wang, Nam Bui, Vivek Bhadri, Madhawa De Silva, Robert Steffner, Nathan A. Yee, Sangeetha Srinivasan, Jose M. Mejia Oneto, M. Wayne Saville, and Vivek Subbiah
Creating PDXs from continental African breast tumors: Addressing racial inequity through science, Evelyn M. Jiagge, Tahra K. Suhan, Jessica M. Bensenhaver, Michele Dziubinski, Joseph K. Oppong, Francis Aitpillah, Awuah Baffour, John D. Carpten, Lisa A. Newman, Sofia D. Merajver, and Max S. Wicha
P10.04 Immunotherapy-Treated Non-Small Cell Lung Cancer Patients With Sensitizing Gene Alterations: A Real World Survival Analysis, Leila Khaddour, C Zhang, Faria Ali, Shirish M. Gadgeel, E Tadesse, M Thompson, D Reding, J Treisman, A Berry, M Izano, C Sweetnam, A Stafford, F Wolf, T Brown, and Igor Rybkin
A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies, Tae Min Kim, Dok Hyun Yoon, Ahmad Mattour, Jorge M. Chaves, Emily Curran, Yoon Kyung Jeon, Bong-Seog Kim, and Seok Jin Kim
Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/ activation in patients with microsatellitestable/ instability-low metastatic colorectal cancer in a phase 1 study, David Krige, Marwan Fakih, Lee Rosen, Ding Wang, Wael Harb, Hani Babiker, Jordan Berlin, Gianfranco Di Genova, David Miles, Mark Powell, and Minesh Patel
CT-423: Neuropsychiatric Disorders in Hospitalized Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma, O Lawal, O Lupak, I Udo, and Josephine Emole
1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy, T A. Leal, D Berz, Igor I. Rybkin, W T. Iams, D Bruno, C Blakely, A Spira, M R. Patel, D M. Waterhouse, D Richards, A Pham, R Jotte, E B. Garon, D Hong, R Shazer, X Yan, L Latven, and K He
Phase 1 study of mRNA-2752, A lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36G, for intratumoral (ITU) injection +/-durvalumab in advanced solid tumors and lymphoma, Manish Patel, Antonio Jimeno, Ding Wang, Salomon Stemmer, Todd Bauer, Randy Sweis, Ravit Geva, Shivaani Kummar, Patrick Reagan, Ruth Perets, and Patricia LoRusso
961MO Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers, M R. Posner, A L. Ho, J Niu, L Nabell, R S. Leidner, J Nieva, D L. Richardson, A T. Pearson, Ding Wang, K Chung, D R. Adkins, A Pimentel, S Wong, C Lacobucci, X Qing, K Katchar, K Schlienger, I Matushansky, S Fu, and D G. Pfister
KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation, G J. Riely, S H.I. Ou, Igor Rybkin, A Spira, K Papadopoulos, J K. Sabari, M Johnson, R S. Heist, L Bazhenova, M Barve, J M. Pacheco, K Velastegui, C Cilliers, P Olson, J G. Christensen, T Kheoh, R C. Chao, and P A. Janne
